HOWL
Werewolf Therapeutics Inc
NASDAQ: HOWL · HEALTHCARE · BIOTECHNOLOGY
$0.68
-8.11% today
Updated 2026-04-29
Market cap
$33.05M
P/E ratio
—
P/S ratio
10.21x
EPS (TTM)
$-1.33
Dividend yield
—
52W range
$1 – $2
Volume
0.4M
Werewolf Therapeutics Inc (HOWL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $4.15M | $16.40M | $19.94M | $1.89M | $0.00 |
| Revenue growth (YoY) | — | — | — | +295.4% | +21.6% | -90.5% | -100.0% |
| Cost of revenue | $463000.00 | $777000.00 | $735000.00 | $2.51M | $1.76M | $1.81M | $1.63M |
| Gross profit | $-463000.00 | $-777000.00 | $-735000.00 | $16.40M | $18.18M | $71000.00 | $-1.63M |
| Gross margin | — | — | -17.7% | 100.0% | 91.2% | 3.8% | — |
| R&D | $6.34M | $16.64M | $35.27M | $53.76M | $41.78M | $56.43M | $44.83M |
| SG&A | $3.60M | $5.76M | $14.82M | $18.70M | $18.67M | $19.05M | $15.85M |
| Operating income | $-9.94M | $-22.40M | $-50.09M | $-56.06M | $-40.50M | $-73.59M | $-60.68M |
| Operating margin | — | — | -1207.5% | -341.8% | -203.1% | -3904.2% | — |
| EBITDA | $-9.41M | $-14.26M | $-49.87M | $-54.95M | $-32.47M | $-64.05M | $-59.04M |
| EBITDA margin | — | — | -1202.3% | -335.1% | -162.8% | -3397.6% | — |
| EBIT | $-9.88M | $-15.04M | $-50.09M | $-56.06M | $-34.23M | $-65.86M | $-60.68M |
| Interest expense | $372000.00 | $101000.00 | $216000.00 | $1.10M | $3.14M | $4.66M | $5.27M |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-10.99M | $-14.94M | $-49.77M | $-51.56M | $-37.37M | $-70.52M | $-60.82M |
| Net income growth (YoY) | — | -35.9% | -233.1% | -3.6% | +27.5% | -88.7% | +13.7% |
| Profit margin | — | — | -1199.8% | -314.4% | -187.4% | -3740.8% | — |